Drug Trial Radar · NCT03891524
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,242
Actual
Start
Jun 17, 2019
Primary completion
Apr 6, 2021
Study completion Apr 6, 2021
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Mar 27, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis \[DVT\] \[asymptomatic confirmed by venography assessment or objectively confirmed symptomatic\], nonfatal pulmonary embolism \[PE\], or any death) during the treatment period.
Conditions
- Arthroplasty, Replacement, Knee
Interventions
JNJ-70033093 25 mgDrug
Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
JNJ-70033093 50 mgDrug
Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.
JNJ-70033093 100 mgDrug
Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.
JNJ-70033093 200 mgDrug
Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
PlaceboDrug
Participants will receive placebo matching to JNJ-70033093, orally.
Enoxaparin 40 mgDrug
Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)Time frame: Up to Day 14
Locations
117 sites in 18 countries. Site status is shown where the registry gives one.
Central Research Associates, Inc.
Birmingham, Alabama
Arizona Research Center
Phoenix, Arizona
Bowen Hefley Orthopedics
Little Rock, Arkansas
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Denver Metro Orthopedics, PC
Englewood, Colorado
DMI Research
Pinellas Park, Florida
Gulfcoast Research Institute
Sarasota, Florida
University Orthopedic and Joint Replacement Center
Tamarac, Florida
Memorial Hermann Memorial City Medical Center
Houston, Texas
Hospital Britanico de Buenos Aires
Buenos Aires, Argentina
Clinica Adventista Belgrano
CABA, Argentina
Hospital San Roque
Córdoba, Argentina
Clínica Chutro
Córdoba, Argentina
Hospital Italiano La Plata
La Plata, Argentina
Instituto de Investigaciones Clinicas Rosario
Rosario, Argentina
Sanatorio Corporación Médica de General San Martín
San Martin, Argentina
ZNA Middelheim
Antwerp, Belgium
Ziekenhuis Oost-Limburg
Genk, Belgium
Jessa Ziekenhuis
Hasselt, Belgium
ZNA Jan Palfijn
Merksem, Belgium
Hospital Sao Francisco de Assis
Belo Horizonte, Brazil
Hospital e Maternidade Dr Christovao da Gama S.A
Santo André, Brazil
Hospital Estadual Mario covas
Santo André, Brazil
University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski
Pleven, Bulgaria
Acibadem City Clinic Tokuda Hospital
Sofa, Bulgaria
University Multiprofile Hospital Sofiamed Sofia
Sofia, Bulgaria
MHAT Tzaritza Joanna
Sofia, Bulgaria
Medical Center - Medical Complex BEROE EOOD
Stara Zagora, Bulgaria
Lakeridge Health
Ajax, Ontario, Canada
Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada
The Ottawa Hospital Research Institute
Ottawa, Ontario, Canada
Medical Investigative and Clinical Evaluation Inc
Windsor, Ontario, Canada
General Hospital of Attiki 'KAT'
Kifissia, Greece
General Hospital of Nea Ionia 'Konstantopoulio'
Nea Ionia, Greece
University General Hospital of Rio Patras
Pátrai, Greece
Papageorgiou General Hospital
Thessaloniki, Greece
Semmelweis Egyetem
Budapest, Hungary
Debreceni Egyetem
Debrecen, Hungary
Petz Aladar Megyei Oktato Korhaz
Gyõr, Hungary
Somogy Megyei Kaposi Mor Oktato Korhaz
Kaposvár, Hungary
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.